Breadcrumb Home Media Press Releases media Press Releases Subscribe to our press releases 2023 08/03/2023 EUROAPI Full-Year 2022 Results_March 8 2023 Download the pdf version 31/01/2023 Progressive restart of prostaglandin production at Budapest site Download the pdf version 11/01/2023 EUROAPI’s Board of Directors proposes Mattias Perjos as independent Director Download the pdf version 09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France Download the pdf version 2022 07/12/2022 EUROAPI updates its 2022 financial guidance Download the pdf version 31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025 Download the pdf version 01/09/2022 Availability of 2022 Half-Year Financial Report Download the pdf version 01/09/2022 EUROAPI 2022 Half-year results Download the pdf version 22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022” Download the pdf version 21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France Download the pdf version 01/07/2022 Availability of EUROAPI’s 2021 half-year results Download the pdf version 09/06/2022 EUROAPI joins the SBF 120 and CAC Mid 60 indices Download the pdf version 03/06/2022 EUROAPI launches its first global employee share plan “EUROAPI Action 2022” Download the pdf version 01/06/2022 EUROAPI implements a liquidity contract with Kepler Cheuvreux Download the pdf version 30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles Download the pdf version 06/05/2022 EUROAPI announces the success of its listing on Euronext Paris Download the pdf version 03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met Download the pdf version 01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022 Download the pdf version
11/01/2023 EUROAPI’s Board of Directors proposes Mattias Perjos as independent Director Download the pdf version
09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France Download the pdf version
31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025 Download the pdf version
22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022” Download the pdf version
21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France Download the pdf version
03/06/2022 EUROAPI launches its first global employee share plan “EUROAPI Action 2022” Download the pdf version
30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles Download the pdf version
03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met Download the pdf version
01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022 Download the pdf version